Radiomer Therapeutics, Inc. is developing Radiomers, targeted radiopharmaceuticals / radioligand therapies, for theranostic applications using its novel Raptamer platform.

Raptamers are a novel targeting vector that consist of a single-stranded (ss)DNA backbone decorated with peptide-like side chains to add chemical diversity and improve binding affinity. The modular Raptamer structure allows the addition of a variety of chelators and isotope payloads.

We have a rich pipeline of promising Radiomers in development. Our lead programs are advancing assets against both well-established and first-in-class cancer targets. We expect to complete our first Phase 0 imaging/dosimetry trial in cancer patients by Q1 2025, to be followed by therapeutic programs.

Raptamers are attractive as a targeting vector for radiopharmaceuticals:

• Raptamer specificities and binding affinities are similar to those of antibodies, but their shorter circulating half-life can be matched to the decay of the radioisotope.

• Raptamers provide for good tissue penetration, a simple manufacturing process, and high temperature stability for easier storage, shipping, and radio-chelation.

• We can rapidly develop high-affinity Raptamers against existing and novel targets, going from target to Raptamer in 2 to 3 months and to clinic in 12 months.

We welcome opportunities to collaborate!